Year: 2022

atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD

Written by Customer Service on October 12, 2022. Posted in Public Companies.

– Initial results showed that single ascending oral dosing of KUR-101 produces dose-dependent analgesia (pain relief) with effects on respiration comparable to that of placebo. – Topline results, including Part 2 comparing a single dose of KUR-101 to a single dose of oxycodone or placebo, are expected by the end of 2022. – KUR-101 is an oral formulation of deuterated mitragynine, the major active alkaloid of the kratom plant, under development for the treatment of opioid use disorder (OUD). – Nearly every 7 minutes, someone dies of an opioid-related overdose. Approximately 3 million people in the U.S. are diagnosed with OUD, and relapse occurs in up to 75% of patients. NEW YORK and BERLIN, Oct. 12, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”) announced today positive initial results for their Phase...

Moderna exercises option to license proprietary targeting technology from Autolus

Written by Customer Service on October 12, 2022. Posted in Public Companies.

– Option exercised on undisclosed immune-oncology target following evaluation period by Moderna – – Autolus receives option exercise fee, with potential for development milestone payments plus royalties – LONDON, Oct. 12, 2022 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programed T cell therapies, today announces that Moderna (MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, has exercised its option to license Autolus’ proprietary binders against an undisclosed immuno-oncology target for the development and commercialization of mRNA therapeutics. This follows an original agreement with Moderna announced on August 2, 2021, granting Moderna an exclusive option to license Autolus’ proprietary...

Tiziana Life Sciences Plans to Submit IND for Phase 1 Trial of Intranasal Foralumab in Alzheimer’s Disease Patients

Written by Customer Service on October 12, 2022. Posted in Public Companies.

Company continues to advance foralumab in CNS-related inflammatory diseases NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that it plans to submit an Investigational New Drug Application (IND) for a Phase 1 Trial of intranasal foralumab in Alzheimer’s disease patients after receiving an affirmative written response from the FDA on a Pre-Investigational New Drug Application (PIND). Tiziana plans on filing the IND for Alzheimer’s disease by the third quarter of 2023 upon the completion of requested toxicology studies, then starting its Phase 1 program by the end of 2023. “I am thrilled to see the company advancing foralumab into another...

GreenLight Biosciences announces realignment to focus on near-term value drivers

Written by Customer Service on October 12, 2022. Posted in Public Companies.

Colorado potato beetle on leaf Close-up of a Colorado potato beetle on a leafBOSTON, Oct. 12, 2022 (GLOBE NEWSWIRE) — GreenLight Biosciences (Nasdaq: GRNA), a public benefit corporation striving to bring effective and safe solutions to make food clean and affordable for everyone and dedicated to developing health solutions for every person on our planet, today announced a realignment to focus on key near-term value drivers and extend its cash runway. Key changes include further optimizing GreenLight’s organizational structure to better serve the company’s operations and more efficiently support the research, development and commercialization of its plant health and human health pipelines, primarily by integrating GreenLight’s platform team into the respective teams for human health and plant health. These integrations...

Eagle Pharmaceuticals Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Treatment of Severe Community-Acquired Bacterial Pneumonia

Written by Customer Service on October 12, 2022. Posted in Public Companies.

— Company plans to commence an adequately powered Phase 2 study with approximately 276 patients with severe community-acquired pneumonia at 120 sites worldwide with patient enrollment expected as early as the beginning of 2023 — — Interim results expected approximately one year after patient enrollment begins — — CAL02 is being developed as an add-on to the clinically indicated antibiotic treatment and potentially offers unique therapeutic benefits to critically ill patients, including immediate decrease in inflammatory biomarkers, shorter duration of critical care management such as mechanical ventilation, and ultimately a reduced mortality risk — WOODCLIFF LAKE, N.J., Oct. 12, 2022 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) announced today that...

Hywin Files Its Fiscal Year 2022 Annual Report on Form 20-F

Written by Customer Service on October 12, 2022. Posted in Public Companies.

SHANGHAI, China, Oct. 12, 2022 (GLOBE NEWSWIRE) — Hywin Holdings Ltd. (“Hywin” or the “Company”) (NASDAQ: HYW), a leading independent wealth management service provider in China, today announced that it has filed its annual report containing its audited consolidated financial statements for the fiscal year ended June 30, 2022 on Form 20-F with the Securities and Exchange Commission (the “SEC”) on October 12, 2022 Eastern Time. The annual report can be accessed on Hywin’s investor relations website at https://ir.hywinwealth.com and on the SEC’s website at http://www.sec.gov. The Company will provide hard copies of the annual report, free of charge, to its shareholders and ADS holders upon request. Requests should be directed to ir@hywinwealth.com. About Hywin Holdings Ltd. Hywin (NASDAQ: HYW) is a leading...

Desktop Virtualization Market Worth $20.1 Billion By 2027 – Exclusive Report by MarketsandMarkets™

Written by Customer Service on October 12, 2022. Posted in Mergers And Acquisitions.

Chicago, Oct. 12, 2022 (GLOBE NEWSWIRE) — Desktop Virtualization Market size is expected to grow from USD 12.3 billion in 2022 to USD 20.1 billion by 2027, at a Compound Annual Growth Rate (CAGR) of 10.3% during the forecast period according to a new report by MarketsandMarkets™. The global Desktop Virtualization Market is gaining traction, with need to increase the productivity of employees, If devices/PCs of employees’ counter hardware issues or are accidentally damaged, employees, with the help of desktop virtualization, can log in from another device and continue working, as data is safe on the server or on the cloud. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=137215705 Browse in-depth TOC on “Desktop Virtualization Market”159 – Tables42 – Figures201 – Pages Scope...

Major shareholder announcement – AIC A/S

Written by Customer Service on October 12, 2022. Posted in Public Companies.

Pursuant to section 30 of the Danish Capital Markets Act, FirstFarms A/S hereby announces to have received information from AIC A/S, that they now own between 10 and 14.99 percent of the shares in FirstFarms A/S. Best regards,FirstFarms A/S For further information:Please visit our website www.firstfarms.com or contact CEO Anders H. Nørgaard on phone +45 75 86 87 87. About FirstFarms:FirstFarms is a Danish stock exchange listed company. We operate FirstFarms with responsibility for the surrounding communities, and we deliver highest quality which is primarily sold locally. We act on new opportunities, that create value for our investors and for the surroundings. Every day, we work on creating a more sustainable company.Attachment(23) Major shareholder announcement – AIC

Thin Wafer Market worth $20.6 billion by 2027 – Exclusive Report by MarketsandMarkets™

Written by Customer Service on October 12, 2022. Posted in Mergers And Acquisitions.

Chicago, Oct. 12, 2022 (GLOBE NEWSWIRE) — Thin Wafer Market is projected to grow from USD 11.4 billion in 2022 to USD 20.6 billion by 2027, at a CAGR of 12.5% during the forecast period from 2022 to 2027, according to a new report by MarketsandMarkets™. Rise in the adoption of MEMS technology in portable health monitoring devices coupled with reduction in the sizes of electronic devices, growing smartphone and consumer electronics markets as well a high amount of material saving is expected to fuel the growth of the thin wafer market. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=255706993 Browse in-depth TOC on “Thin Wafer Market”123 – Tables45 – Figures197 – Pages Thin wafer market for LED application expected to witness the highest growth during the forecast period. The LED application segment...

Stantec signs letter of intent to acquire Philadelphia-based L2P, deepening Mid-Atlantic architecture expertise

Written by Customer Service on October 12, 2022. Posted in Mergers And Acquisitions.

Air Products Global Headquarters L2P provided master planning, workplace strategy, architecture, and interior design for the global headquarters of Air Products, a leading industrial gases company.EDMONTON, Alberta and NEW YORK and PHILADELPHIA, Oct. 12, 2022 (GLOBE NEWSWIRE) — TSX, NYSE: STN Stantec, a global leader in sustainable architecture, interior design, and engineering, has signed a Letter of Intent to acquire L2P, a 40-person Philadelphia-based architecture, interior design, and planning firm. Founded in 2009, L2P has grown to be a trusted advisor in the science and technology, commercial workplace, higher education, residential, and hospitality markets. The terms of the transaction are not disclosed. The acquisition will bolster Stantec’s science and technology and commercial workplace offerings in greater Philadelphia...

Year: 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals